Oberweis Asset Management Inc. Grows Stake in LivaNova PLC (NASDAQ:LIVN)

Oberweis Asset Management Inc. boosted its position in LivaNova PLC (NASDAQ:LIVN - Free Report) by 54.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 440,535 shares of the company's stock after purchasing an additional 155,850 shares during the period. LivaNova comprises 1.0% of Oberweis Asset Management Inc.'s portfolio, making the stock its 25th biggest holding. Oberweis Asset Management Inc. owned about 0.81% of LivaNova worth $20,401,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in LIVN. Russell Investments Group Ltd. boosted its holdings in shares of LivaNova by 17.1% in the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock worth $70,000 after buying an additional 219 shares during the last quarter. Sterling Capital Management LLC lifted its position in shares of LivaNova by 800.6% during the 4th quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock valued at $75,000 after buying an additional 1,441 shares in the last quarter. Central Pacific Bank Trust Division lifted its holdings in LivaNova by 21.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company's stock valued at $191,000 after purchasing an additional 720 shares in the last quarter. Vestcor Inc bought a new position in LivaNova in the 4th quarter worth $204,000. Finally, Optimize Financial Inc bought a new position in LivaNova in the 4th quarter worth $208,000. 97.64% of the stock is currently owned by institutional investors.

LivaNova Price Performance

Shares of NASDAQ LIVN traded up $0.25 during midday trading on Monday, reaching $37.51. 507,012 shares of the stock traded hands, compared to its average volume of 623,166. The company's 50 day moving average is $38.94 and its 200 day moving average is $46.10. LivaNova PLC has a one year low of $32.48 and a one year high of $64.48. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The stock has a market capitalization of $2.04 billion, a PE ratio of 89.31 and a beta of 0.90.

Analyst Ratings Changes

Several equities analysts have recently commented on LIVN shares. The Goldman Sachs Group lowered their price objective on LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research report on Monday, March 3rd. Needham & Company LLC restated a "buy" rating and issued a $64.00 price target on shares of LivaNova in a research note on Monday, March 17th. StockNews.com raised shares of LivaNova from a "buy" rating to a "strong-buy" rating in a report on Tuesday, March 25th. Wolfe Research downgraded shares of LivaNova from an "outperform" rating to a "peer perform" rating in a report on Wednesday, February 26th. Finally, Mizuho cut their target price on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research note on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, LivaNova currently has a consensus rating of "Buy" and a consensus price target of $61.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.